BioCentury
ARTICLE | Company News

Teva, Heptares strike migraine deal

November 26, 2015 12:04 AM UTC

The Heptares Therapeutics Ltd. subsidiary of Sosei Group Corp. (Tokyo:4565) granted Teva Phamaceutical Industries Ltd. (NYSE:TEVA) exclusive, worldwide rights to develop preclinical, small molecule calcitonin gene-related peptide ( CGRP) antagonists to treat migraine.

Heptares received $10 million up front and is eligible for $400 million in milestones, plus royalties. ...